Holm T, Singnomklao T, Rutqvist L E, Cedermark B
Department of Surgery, Karolinska Hospital, Stockholm, Sweden.
Cancer. 1996 Sep 1;78(5):968-76. doi: 10.1002/(SICI)1097-0142(19960901)78:5<968::AID-CNCR5>3.0.CO;2-8.
Adjuvant preoperative radiotherapy of patients with primary rectal carcinoma improves local control and survival, but also may increase the risk of early postoperative morbidity and mortality. In addition, the possible late adverse effects of this treatment are largely unknown.
The present study was based on 1027 curatively operated patients included in 2 prospective randomized trials of preoperative radiotherapy for rectal carcinoma patients (Stockholm I and Stockholm II Trials). The goal was to assess whether long term intercurrent morbidity and mortality were increased in patients allocated to the preoperative treatment. A computerized linkage of the randomized patients to a population-based registry of the Stockholm County Council was used to study hospital admissions for six groups of a priori defined diseases, putatively related to late adverse effects of the radiation.
Preoperative radiotherapy significantly increased the incidence of venous thromboembolism (P = 0.01), femoral neck and pelvic fractures (P = 0.03), intestinal obstruction (P = 0.02), and postoperative fistulas (P = 0.01). For arterial disease and genitourinary tract diseases, no difference in risk was found between irradiated and non irradiated patients. Radiotherapy significantly reduced rectal carcinoma deaths in both trials and also improved overall survival in the Stockholm II trial. The late intercurrent mortality was similar in irradiated and nonirradiated patients.
Although high dose, short term, preoperative radiotherapy can improve outcome after surgery for rectal carcinoma, there also may be an increased risk for long term morbidity. Refinement of the radiotherapy technique and a more accurate selection of patients suitable for the treatment will probably further improve the results, at least in regard to treatment-related complications.
原发性直肠癌患者术前辅助放疗可改善局部控制率和生存率,但也可能增加术后早期发病和死亡风险。此外,这种治疗可能产生的晚期不良反应在很大程度上尚不清楚。
本研究基于1027例接受根治性手术的患者,这些患者纳入了两项直肠癌患者术前放疗的前瞻性随机试验(斯德哥尔摩I和斯德哥尔摩II试验)。目的是评估接受术前治疗的患者长期并发疾病和死亡率是否增加。通过将随机分组的患者与斯德哥尔摩县议会基于人群的登记系统进行计算机链接,研究六组预先定义疾病的住院情况,这些疾病被认为与放疗的晚期不良反应有关。
术前放疗显著增加了静脉血栓栓塞(P = 0.01)、股骨颈和骨盆骨折(P = 0.03)、肠梗阻(P = 0.02)和术后瘘管(P = 0.01)的发生率。对于动脉疾病和泌尿生殖道疾病,放疗组和未放疗组患者的风险没有差异。放疗在两项试验中均显著降低了直肠癌死亡率,在斯德哥尔摩II试验中还改善了总生存率。放疗组和未放疗组患者的晚期并发死亡率相似。
尽管高剂量、短期术前放疗可改善直肠癌手术后的预后,但长期发病风险可能也会增加。放疗技术的改进以及更准确地选择适合该治疗的患者可能会进一步改善结果,至少在治疗相关并发症方面。